2M ENGINEERING LIMITED

Their core work

2M Engineering is a UK-based SME specializing in biophotonic and optical sensing technologies for medical diagnostics. Their work spans from developing non-invasive glucose monitoring devices using Raman spectroscopy to endoscopic imaging systems for bladder cancer detection. More recently, they have contributed to cardiovascular research as a third-party specialist, suggesting they provide engineering or instrumentation expertise to larger research consortia working on thrombo-inflammatory diseases.

What they specialise in

How they've shifted over time

2M Engineering entered H2020 in 2014 with a focused SME Instrument Phase 1 project on non-invasive glucose monitoring using Raman spectroscopy — a classic medtech startup feasibility study. By 2016-2021, they had moved into a larger collaborative project (MIB) on endoscopic biophotonic imaging for bladder cancer, receiving over EUR 500K and working within a bigger consortium. Their most recent involvement (TICARDIO, 2019-2023) as a third party in a Marie Curie training network on cardiovascular thrombo-inflammation suggests a broadening from device development toward contributing specialized engineering capabilities to wider biomedical research programmes.

Moving from standalone device development toward embedding their optical/photonic engineering expertise into larger biomedical research consortia, which could make them a valuable instrumentation partner for future health projects.

How they like to work

2M Engineering has played all three roles — coordinator, participant, and third party — across just three projects, showing flexibility in how they engage. Their 20 unique consortium partners across 6 countries indicate they integrate well into medium-sized European consortia rather than leading large ones. Their progression from coordinating a small Phase 1 feasibility study to participating in larger RIA and MSCA networks suggests a company that is growing its collaborative footprint strategically.

They have worked with 20 partners across 6 countries, primarily through health-focused consortia. The bulk of their network likely comes from the MIB and TICARDIO projects, giving them connections in both clinical imaging and cardiovascular research communities.

What sets them apart

2M Engineering sits at the intersection of optical engineering and clinical diagnostics — a niche where few SMEs operate. Their ability to move from Raman spectroscopy for glucose to endoscopic biophotonics for cancer to cardiovascular research tools shows versatile instrumentation expertise. For consortium builders, they offer hands-on engineering and prototyping capacity that bridges the gap between laboratory optics research and clinical-grade device development.

Highlights from their portfolio

• MIB
  Largest funding (EUR 502K) and longest duration — a multi-partner RIA on endoscopic biophotonic imaging for point-of-care bladder cancer diagnosis.
• NiGlucoMon
  Their only coordinator role, an SME Instrument Phase 1 feasibility study for a non-invasive glucose monitor using Stimulated Raman Spectroscopy.
• TICARDIO
  A Marie Curie training network on cardiovascular thrombo-inflammation, showing the company's expansion into new biomedical domains as a specialist third party.